Lee 2007.

Methods	Study design: 4 group factorial design, parallel RCT Power calculation: yes Intention‐to‐treat analysis: yes
Participants	Inclusion criteria Setting: spinal cord injuries database, predominantly community dwelling patients Country: Australia Spnal cord injured people with neurogenic bladder, bladder management with either indwelling urethral or suprapubic catheter, intermittent catheterization, or reflex voiding with or without a condom drainage divide, absence of complex urological or serious renal or hepatic pathology, not being prescribed antibiotics at the time of enrolment and absence of symptoms of a UTI at enrolment. Had to be willing to stop any intercurrent urinary antiseptics before entering the study, Number: 305 randomised/analysed Mean age: 43.5 years Sex: 253 males Exclusion criteria Previous allergy to any of the test interventions
Interventions	Treatment group 1 Methenamine hippurate: 2 g Cranberry: 1600 mg Treatment group 2 Methenamine hippurate: 2 g Cranberry placebo Treatment group 3 Cranberry: 1600 mg Methenamine hippurate placebo Control group Methenamine hippurate placebo Cranberry placebo
Outcomes	Symptomatic UTI: current criteria for treating patients in the spinal injured population
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Dynamically balanced, centralized randomisation performed externally
Allocation concealment (selection bias)	Low risk	External trial centre controlled, sent to pharmacy
Blinding of participants and personnel (performance bias) All outcomes	Low risk	States all staff and participants were blinded
Blinding of outcome assessment (detection bias) All outcomes	Low risk	States all staff were blinded
Incomplete outcome data (attrition bias) All outcomes	Low risk	All accounted for in results
Selective reporting (reporting bias)	Low risk	Well described
Other bias	Low risk	No other bias apparent, well reported study Source of funding: Motor accidents authority and Brucia Pharmaceuticals